Bristol-Myers Squibb’s Breyanzi Hits Primary Endpoint in Lymphoma Study
Bristol-Myers Squibb (BMS, NYSE: BMY) reported positive results from the Phase II TRANSCEND FL study...
BMS
Sichuan Kelun-Biotech’s Datailai Gains NMPA Approval for Colorectal Cancer Treatment
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that it has received marketing approval...
Bristol-Myers Squibb Posts 8% Q4 Revenue Growth, Driven by Opdivo and New Products
Bristol-Myers Squibb (BMS, NYSE: BMY) reported an 8% year-on-year (YOY) increase in revenues to USD...
Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has resubmitted its application...
Bristol-Myers Squibb’s Opdivo Qvantig Receives FDA Approval for Expanded Indications
Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that the US Food and...
Bristol-Myers Squibb’s Sotyktu Meets Primary Endpoints in POETYK PsA Studies
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from the pivotal...
Bristol-Myers Squibb’s Opdivo-Yervoy Combo Approved by EC for MSI-H/mCRC
Global biopharmaceutical company Bristol-Myers Squibb (BMS, NYSE: BMY) has announced that it has received marketing...
BioArctic AB Secures Global Rights to PyroGlu-Aβ Antibody Program in BMS Deal
Sweden-based BioArctic AB (OTCMKTS: BRCTF) has announced a significant licensing agreement with US pharmaceutical giant...
Fangzhou Inc. Partners with BMS to Innovate Digital Medicine Platform
China-based Internet healthcare solutions provider Fangzhou Inc. (HKG: 6086) has entered into a partnership with...
BMS Regains Exclusive Rights to ABZ-706 in Greater China
Bristol-Myers Squibb (BMS; NYSE: BMY) has reached an agreement with China-based Ablaze Pharmaceuticals to regain...
AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics
US-based biotech AI Proteins, Inc. has entered into a research collaboration and option agreement with...
Sichuan Biokin Pharmaceutical’s BL-M08D1 ADC Receives NMPA Approval for Clinical Trials
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
EMA’s CHMP Recommends Approval for BMS’s Opdivo/Yervoy Combo in mCRC
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
BMS’s Opdivo Secures NMPA Approval for Urothelial Carcinoma Treatment
Bristol Myers Squibb (BMS; NYSE: BMY) has announced that it has received another indication approval...
Legend Biotech Corporation Appoints Alan Bash as President of Carvykti
China-based chimeric antigen receptor (CAR) T cell therapy specialist, Legend Biotech Corporation (NASDAQ: LEGN), has...
AbbVie Partners with EvolveImmune to Develop Immunotherapies for Cancer
US pharmaceutical company AbbVie (NYSE: ABBV) has entered into a collaboration and option-to-license agreement with...
LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control...
BMS Launches Cardiac Myosin Inhibitor Camzyos in China for Obstructive Hypertrophic Cardiomyopathy
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin...
BMS’s Dual Immunotherapy Achieves Global First Approval for MSI-H/dMMR CRC in China
On October 14, 2024, Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the National Medical Products...
BeiGene Prices TEVIMBRA 10% Below Competitors Following FDA Approval for Esophageal Cancer Treatment
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced the commercial availability of TEVIMBRA (Tislelizumab)...